What medications should every patient receive at discharge after an acute myocardial infarction?

Essential Discharge Medications After Myocardial Infarction

Every patient discharged after an MI should receive aspirin, a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), a beta-blocker, a high-intensity statin, and an ACE inhibitor (or ARB if ACE inhibitor intolerant), unless specific contraindications exist. 1, 2, 3

Core Medication Classes (The "ABCDE" Framework)

1. Antiplatelet Therapy - Dual Antiplatelet Therapy (DAPT)

Aspirin:

• Loading dose: 162-325 mg initially 3
• Maintenance: 81 mg daily indefinitely 1, 2, 3
• If true aspirin allergy exists, use clopidogrel 75 mg daily as substitute 4, 5

P2Y12 Inhibitor (choose one):

• Ticagrelor 90 mg twice daily (preferred over clopidogrel) 1, 2
• Prasugrel 10 mg daily (if patient received stent) 1
• Clopidogrel 75 mg daily (if ticagrelor/prasugrel contraindicated) 1, 2

Continue DAPT for at least 12 months in all ACS patients 1, 2. The 2014 AHA/ACC guidelines explicitly state ticagrelor is reasonable to use in preference to clopidogrel 2, reflecting superior outcomes in reducing cardiovascular death.

2. Beta-Blockers

Prescribe at discharge for all patients without contraindications 4, 1, 6. Beta-blockers reduce mortality and recurrent MI through multiple mechanisms including heart rate reduction, decreased myocardial oxygen demand, and antiarrhythmic effects. The evidence supporting beta-blockers is Level A 4, 6.

3. Cholesterol Management - High-Intensity Statins

Critical point: Prescribe a high-intensity statin regardless of baseline LDL cholesterol level 6.

• Target: LDL-C substantially less than 100 mg/dL 6
• High-intensity options: Atorvastatin 40-80 mg or Rosuvastatin 20-40 mg daily
• Prescribe at discharge, not as an outpatient follow-up plan 6

Common pitfall: Only 27-38% of MI patients receive high-intensity statins at discharge despite clear guideline recommendations 7. Many physicians inappropriately continue pre-MI statin doses or prescribe moderate-intensity statins. The evidence shows high-intensity statins reduce mortality and recurrent events more than moderate doses in ACS patients 7.

4. ACE Inhibitors (or ARBs)

ACE inhibitor indications (Class I, Level A):

• All patients after STEMI without contraindications 5
• Particularly essential if: LV dysfunction (EF ≤40%), heart failure, hypertension, or diabetes 4, 6

ARB as alternative:

• Use if ACE inhibitor intolerant AND patient has heart failure or LVEF <40% 6, 5
• Valsartan and candesartan have established efficacy 5

5. Additional Considerations

Aldosterone antagonist:

• Add for post-MI patients with LVEF ≤40% AND either symptomatic heart failure or diabetes, if already on therapeutic ACE inhibitor dose 5
• Requires: Creatinine ≤2.5 mg/dL (men) or ≤2.0 mg/dL (women), and potassium ≤5.0 mEq/L 5

Nitroglycerin:

• Provide sublingual or spray formulation with explicit instructions 4, 2, 8, 9
• Instruct: If chest pain lasts >1 minute, take 1 dose; if no relief in 3-5 minutes, call 911 immediately 2

Critical Implementation Points

Avoid these common errors:

1. Statin underdosing: The single most important predictor of receiving high-intensity statin is the pre-MI dose 7. Break this pattern—prescribe high-intensity regardless of prior therapy.

2. Delaying lipid assessment: Document LDL-C level during hospitalization or ensure testing is scheduled 6. Don't discharge without addressing lipid management.

3. Omitting ACE inhibitors in "stable" patients: ACE inhibitors benefit extends beyond those with obvious heart failure—prescribe for all STEMI patients 5.

4. Inadequate patient education: Provide written and verbal instructions about medication purpose, dosing, and what to do if symptoms recur 4, 2, 8, 9. Document this education.

Medication Reconciliation Algorithm

Before discharge, verify:

• ✓ Aspirin 81 mg daily prescribed
• ✓ P2Y12 inhibitor prescribed (preferably ticagrelor)
• ✓ Beta-blocker prescribed (unless contraindicated)
• ✓ High-intensity statin prescribed
• ✓ ACE inhibitor prescribed (or ARB if intolerant)
• ✓ Sublingual nitroglycerin provided
• ✓ Written discharge instructions given
• ✓ Follow-up appointment scheduled

The 2014 and 2025 guidelines emphasize that these medications should be continued indefinitely after discharge, with the anti-ischemic regimen used in-hospital transitioned to an appropriate outpatient regimen 1, 2, 3. Performance measures specifically track these discharge medications because they directly impact mortality and quality of life 6.